<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00359736</url>
  </required_header>
  <id_info>
    <org_study_id>CLIN-009-05F</org_study_id>
    <nct_id>NCT00359736</nct_id>
  </id_info>
  <brief_title>Sildenafil Study to Treat Idiopathic Pulmonary Fibrosis</brief_title>
  <official_title>Vasodilator Therapy and Exercise Tolerance in IPF Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VA Office of Research and Development</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>VA Office of Research and Development</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Medicines that decrease blood pressure in the lungs may help idiopathic pulmonary fibrosis
      (IPF) patients function better. This study will test whether sildenafil improves the ability
      to exercise in patients with pulmonary fibrosis of unknown cause.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Idiopathic pulmonary fibrosis (IPF) is recognized as a predominantly noninflammatory paradigm
      of lung fibrosis, characterized by heterogeneous myofibroblast proliferation (usual
      interstitial pneumonia [UIP]) and a poor clinical prognosis. To date no therapies have been
      demonstrated in well-designed, randomized, controlled trials (RCT) to favorably influence
      functional status or survival of IPF patients. The need for effective therapies for VA
      patients with IPF is thus obvious and urgent.

      The overall goal of this VA Merit Review clinical research is to generate rigorous
      preliminary data for evaluation of a new and potentially effective therapy for IPF. The
      established, combined Miami Veterans Affairs Medical Center (VAMC) - University of Miami (UM)
      IPF program has participated productively in a number of clinical trials to assess new agents
      for the therapy of IPF (e.g., interferon gamma-lb, imatinib mesylate, etanercept, bosentan).
      Our program is uniquely qualified to enroll large numbers of IPF patients in clinical trials,
      because of its large metropolitan population base (&gt;5,000,000 people) and extensive referral
      network throughout South and Central America. The Veteran population of South Florida (Dade,
      Broward and Monroe Counties) is approximately 236,000 (U.S. Census Bureau). Of that number
      39% are 65 years of age or older, making them at high risk for IPF. Because of its large
      Veteran and civilian population base, international referral network and previous experience
      as a &quot;high enrollment center&quot; in IPF clinical trials, the Miami VAMC-UM IPF program is
      uniquely qualified to anticipate the role of a CSP lead center.

      Our central hypothesis is that sildenafil, a vasodilator, will have a beneficial effect
      compared to placebo on disease progression, defined as a significant change in the 6-minute
      walk distance or dyspnea index, in patients with IPF.

      Specifically, we will test effects of sildenafil on IPF patients' exercise tolerance and
      level of dyspnea in a double blind, randomized, placebo controlled (one to one assignment)
      pilot study. Upon completion of this trial, it will be possible to assess efficacy of
      sildenafil on progression of disease in IPF and possibly introduce this agent into
      translational practice. Our specific objectives are:

      Specific Objectives 1: To assess the possible therapeutic benefit of a vasodilator,
      sildenafil, on exercise tolerance in IPF patients.

      The working hypothesis is that, compared to placebo, sildenafil will favorably affect rate of
      decline from baseline in exercise capacity (6-minutes walk).

      Specific Objective 2: To assess and compare changes from baseline in pre- and post-exercise
      dyspnea in sildenafil and placebo control groups.

      The working hypothesis is that application of this agent will lead to more sustained exercise
      and a more favorable clinical outcome in addition to a decrease in the degree of limiting
      dyspnea after exercise.

      The application of vasodilator therapy in IPF is unique in that it directly targets key
      pathophysiologic mechanisms of functional limitation: Increased pulmonary vascular resistance
      and dyspnea due to exercise. This novel approach will have a significant impact on field,
      because it promises both additional insight into mechanisms of disease and immediate
      therapeutic options.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2006</start_date>
  <completion_date type="Actual">June 2009</completion_date>
  <primary_completion_date type="Actual">October 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in 6-minute Walk Test</measure>
    <time_frame>0 - 6 months</time_frame>
    <description>Distance in meters -- Distance (meters) walked in 6 minutes</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dyspnea Score (Borg Scale)</measure>
    <time_frame>0 - 6 months</time_frame>
    <description>The Dyspnea score or Borg Rating of Perceived Exertion (RPE) Scale score is a subjective rating of perceived exertion. In medicine this is used to document the patient's effort and exertion, breathlessness and fatigue during a physical test.
The Dyspnea score ranges from 0 (No breathlessness at all) to 10 (Maximum or extremely strong breathlessness).
IN this study the Specific Objective 2 was to assess and compare changes from baseline in pre- and post-exercise dyspnea in the sildenafil and placebo control groups.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">29</enrollment>
  <condition>Alveolitis, Fibrosing</condition>
  <condition>Fibrosis, Pulmonary</condition>
  <condition>Hypertension, Pulmonary</condition>
  <arm_group>
    <arm_group_label>Sildenafil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sildenafil 20 mg tid orally</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Identical Placebo 20 mg tid orally</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sildenafil</intervention_name>
    <description>Assessing the possible therapeutic benefit of sildenafil on exercise tolerance in IPF patients.</description>
    <arm_group_label>Sildenafil</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Revatio</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of IPF

          -  40-85 years of age

          -  6-minute walk distance 150-500 m

          -  FVC 40-90% predicted

          -  DLCO 30-90% predicted

        Exclusion Criteria:

          -  Severe pulmonary hypertension

          -  Severe heart failure

          -  FEV1/FVC &lt; 0.7
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert M Jackson, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>VA Medical Center, Miami</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>VA Medical Center, Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33125</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Jackson RM, Glassberg MK, Ramos CF, Bejarano PA, Butrous G, Gómez-Marín O. Sildenafil therapy and exercise tolerance in idiopathic pulmonary fibrosis. Lung. 2010 Apr;188(2):115-23. doi: 10.1007/s00408-009-9209-8. Epub 2009 Dec 12.</citation>
    <PMID>20012639</PMID>
  </results_reference>
  <results_reference>
    <citation>Jackson R, Ramos C, Gupta C, Gomez-Marin O. Exercise decreases plasma antioxidant capacity and increases urinary isoprostanes of IPF patients. Respir Med. 2010 Dec;104(12):1919-28. doi: 10.1016/j.rmed.2010.07.021. Epub 2010 Aug 23.</citation>
    <PMID>20739168</PMID>
  </results_reference>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 31, 2006</study_first_submitted>
  <study_first_submitted_qc>July 31, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 2, 2006</study_first_posted>
  <results_first_submitted>September 10, 2013</results_first_submitted>
  <results_first_submitted_qc>September 29, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 6, 2014</results_first_posted>
  <last_update_submitted>September 29, 2017</last_update_submitted>
  <last_update_submitted_qc>September 29, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>alveolitis, fibrosing</keyword>
  <keyword>exercise, aerobic</keyword>
  <keyword>fibrosis, pulmonary</keyword>
  <keyword>hypertension, pulmonary</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
    <mesh_term>Hypertension, Pulmonary</mesh_term>
    <mesh_term>Pulmonary Fibrosis</mesh_term>
    <mesh_term>Idiopathic Interstitial Pneumonias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sildenafil Citrate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>2006-2009; U Miami and VA IPF clinics</recruitment_details>
      <pre_assignment_details>Some were excluded after enrollment, because they did not meet entry criteria.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Sildenafil</title>
          <description>Sildenafil 20 mg TID orally : Assessing the possible therapeutic benefit of sildenafil on exercise tolerance in IPF patients.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Control group: Identical Placebo 20 mg TID orally</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Sildenafil</title>
          <description>Sildenafil 20 mg TID orally: Assessing the possible therapeutic benefit of sildenafil on exercise tolerance in IPF patients.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Identical Placebo: 20 mg TID orally</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="14"/>
            <count group_id="B2" value="15"/>
            <count group_id="B3" value="29"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="69.9" spread="12.0"/>
                    <measurement group_id="B2" value="71.0" spread="6.2"/>
                    <measurement group_id="B3" value="70.4" spread="9.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Secondary</type>
        <title>Dyspnea Score (Borg Scale)</title>
        <description>The Dyspnea score or Borg Rating of Perceived Exertion (RPE) Scale score is a subjective rating of perceived exertion. In medicine this is used to document the patient's effort and exertion, breathlessness and fatigue during a physical test.
The Dyspnea score ranges from 0 (No breathlessness at all) to 10 (Maximum or extremely strong breathlessness).
IN this study the Specific Objective 2 was to assess and compare changes from baseline in pre- and post-exercise dyspnea in the sildenafil and placebo control groups.</description>
        <time_frame>0 - 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sildenafil</title>
            <description>Sildenafil 20 mg tid
sildenafil: Assessing the possible therapeutic benefit of sildenafil on exercise tolerance in IPF patients.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Identical Placebo 20 mg tid</description>
          </group>
        </group_list>
        <measure>
          <title>Dyspnea Score (Borg Scale)</title>
          <description>The Dyspnea score or Borg Rating of Perceived Exertion (RPE) Scale score is a subjective rating of perceived exertion. In medicine this is used to document the patient's effort and exertion, breathlessness and fatigue during a physical test.
The Dyspnea score ranges from 0 (No breathlessness at all) to 10 (Maximum or extremely strong breathlessness).
IN this study the Specific Objective 2 was to assess and compare changes from baseline in pre- and post-exercise dyspnea in the sildenafil and placebo control groups.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pre-Exercise Dypsnea score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.86" spread="1.77"/>
                    <measurement group_id="O2" value="0.38" spread="1.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-Exercise Dypsnea score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.89" spread="2.11"/>
                    <measurement group_id="O2" value="0.15" spread="1.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change in 6-minute Walk Test</title>
        <description>Distance in meters -- Distance (meters) walked in 6 minutes</description>
        <time_frame>0 - 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Sildenafil</title>
            <description>Sildenafil 20 mg tid orally</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Identical Placebo 20mg tid orally</description>
          </group>
        </group_list>
        <measure>
          <title>Change in 6-minute Walk Test</title>
          <description>Distance in meters -- Distance (meters) walked in 6 minutes</description>
          <units>meters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-26" spread="45"/>
                    <measurement group_id="O2" value="-7" spread="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 years</time_frame>
      <desc>No additional follow up</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Control group</description>
        </group>
        <group group_id="E2">
          <title>Sildenafil</title>
          <description>sildenafil : Assessing the possible therapeutic benefit of sildenafil on exercise tolerance in IPF patients.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Change in vision</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Robert M Jackson, ACOS/R</name_or_title>
      <organization>Miami VAHS</organization>
      <phone>305-575-3548</phone>
      <email>robert.jackson4@va.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

